Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.

Abstract: A process for producing a surfactant having two head groups and a single tail group per molecule, including steps of: producing a compound of Formula (1) from ethanol and carbon disulfide; producing a compound of Formula (2) from a carboxylic acid and bromine; producing a compound of Formula (3) from the compound of Formula (2) and methanol; producing a compound of Formula (4) from the compound of Formula (1) and the compound of Formula (3); and producing a compound of Formula (5) from the compound of Formula (4) by a direct oxidation process or by a peracid oxidation process. The surfactant produced by the process has lower critical micelle concentration and enables a lower surface tension of a liquid as compared with prior surfactants with two head groups per molecule, thereby enabling the amount of surfactant required and thus the cost to be substantially reduced.

Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Abstract: A process for producing alkyl methacrylates, in particular methyl methacrylate (MMA), includes production of methacrolein (MAL) in a first reaction stage; direct oxidative esterification (DOE) of the methacrolein with an alcohol, preferably methanol, to afford an alkyl methacrylate in a second reaction stage; and workup of the alkyl methacrylate crude product from the second reaction stage. An optimized workup of the reactor output from the oxidative esterification of methacrolein involves minimizing the amount of employed water, the amount of employed acid, and/or the amount of aqueous waste streams, through an optimized recycling of the generated process water streams.

Abstract: Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT. The crystalline forms may be used in the synthesis of elamipretide.

Abstract: The present invention provides novel compounds (e.g., compounds of Formula I) which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: Anti-viral compounds with low cytotoxicity are identified from screening of products found in Red Sea sponges, including the sponge Stylissa carteri. The identified compounds can be brominated pyrrole-2-aminoimidazole alkaloids and derivatives thereof. Specific examples of identified compounds include oroidin, hymenialdisine, and debromohymenialdisine, as well as derivatives thereof. The compounds also can be useful scaffolds or pharmacores for further chemical modification and derivatization. Selected compounds, particularly oroidin, show selective anti-viral HIV-1 activity coupled with reduced cytotoxicity. The compounds can function as HIV reverse-transcriptase inhibitors, and molecular modeling can be used to confirm inhibition.

Abstract: A medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.

Abstract: The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies.

Abstract: A tubular reactor comprises a tubular shell, an external jacket, and a gas distribution device at the top of the shell, wherein at least one group of feed nozzles are distributed uniformly on the shell, each group comprising at least one phosgene nozzle and at least one diamine nozzle; a reaction material is sprayed through the nozzles and impinges with each other in a middle impingement zone to strengthen the reaction effect, the gas distribution device is arranged at the top of the shell and the upper part of the feed nozzle, and an inert medium distributed uniformly through the gas distribution device is refracted at the top of the shell into an impingement reaction zone, so as to reduce the temperature and concentration of the reaction zone.

Abstract: The current invention relates to a method of isolating polyunsaturated fatty acids containing lipids from a lipids containing biomass. The method involves providing a suspension of cells with a PUFAs-containing lipid; optionally lysing the cells; concentrating the suspension; adding base equivalents to the suspension based on the total dry matter present; feeding a continuous reactor with the suspension; and separating the lipids-containing light phase from the water and cell debris-containing heavy phase.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.

Abstract: The present invention relates generally to abuse-deterrent formulations containing dextroamphetamine sulfate.

Abstract: Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for preparing the inclusion complexes, compositions or pharmaceutical formulations.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: In the embodiments, an aqueous hydrochloric acid solution and an organic solvent instead of hydrogen chloride gas and solid triphosgene instead of phosgene gas may be used in the process of preparing a diisocyanate from a diamine through a diamine hydrochloride. In addition, the embodiments provide processes for preparing a diisocyanate composition and an optical lens, which are excellent in yield and quality with mitigated environmental problems by controlling the total content of metals, cations, or anions in a diamine hydrochloride composition.

Abstract: The present disclosure provides for a composition which may be used for the solubilization of an agent or the oral administration of an agent, the composition comprising, a lysophosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lysophosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lysophosphatidyl compound, a monoglyceride and a free fatty acid.

Abstract: An object of the present invention is to provide a novel method for producing a fluorine-containing methylene compound. The above object can be achieved by a method for producing a compound represented by formula (1): wherein R1 represents an organic group, RA represents hydrogen or fluorine, R4a represents hydrogen or an organic group, R4b represents hydrogen or an organic group, R5a represents hydrogen or an organic group, R5b represents hydrogen or an organic group, and R2 represents hydrogen or an organic group; R2 is optionally connected to R4a to form a ring; the method comprising step A of reacting a compound represented by formula (2): wherein X1 represents a leaving group, and other symbols are as defined above, with a compound represented by formula (3): wherein X2 represents a leaving group, and other symbols are as defined above, in the presence of a reducing agent as desired, under light irradiation.

Abstract: The present invention relates to a specialized pro-resolving lipid mediator comprising maresins, D-series resolvins, E-series resolvins, protectins or lipoxins, or a combination thereof, for use in the treatment of neurodegenerative diseases and/or autoimmune diseases.